Trials / Recruiting
RecruitingNCT04996823
Axitinib + Ipilimumab in Advanced Melanoma
Phase 2 Study of Axitinib + Ipilimumab in Advanced Melanoma
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical research study is to find out if taking axitinib with ipilimumab is effective in treating advanced melanoma.
Detailed description
The safety and tolerability of the combination of ipilimumab and axitinib will be tested in advanced melanoma patients who are intolerable/refractory to anti-PD-1/PD-L1 therapy and have not previously received treatment with ipilimumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ipilimumab | Participants will receive ipilimumab 3mg/kg IV every 3 weeks for up to 4 doses. |
| DRUG | Axitinib | Participants will take 5 mg Axitinib twice daily by mouth for up to 35 cycles (24 months) |
Timeline
- Start date
- 2021-08-04
- Primary completion
- 2026-08-20
- Completion
- 2027-03-29
- First posted
- 2021-08-09
- Last updated
- 2025-12-04
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04996823. Inclusion in this directory is not an endorsement.